It is currently Thu Jul 29, 2010 12:11 pm

Debio 0932 (formerly CUDC-305) is a small molecule inhibitor of Heat Shock Protein 90 (Hsp90). Debio0932 is expected to enter Phase I clinical testing in early Q1 2010.

News of HSP90 Debio-0932 (CUDC-305) » Site map of HSP90 Debio-0932 (CUDC-305)

About Debio-0932 (CUDC-305)
on Thu Feb 11, 2010 5:12 pm
CUDC-305 / Debio HSP90 overcomes erlotinib resistance
on Thu Feb 11, 2010 5:16 pm

Last 15 active topics

Hedgehog Pathway Cancers Clinical Trials

Hedgehog Pathway Clinical Implications

CUDC-101 (HDAC/EGFR/Her2 inhibitor)

CUDC-101 Medicinal Chemistry Information

Hedgehog Pathway Articles

Feb-2010 Hedgehog Pathway Articles

HSP90 Debio-0932 (CUDC-305)

Hedgehog Pathway Diagrams and Animations

Hedgehog Pathway Images and Videos

Hedgehog Pathway Cancer and Metastasis

Hedgehog Pathway Cancer and Metastasis

Statistics

Total posts 31 • Total topics 21 • Total members 10

GYM sitemaps & RSS

Curis Hedgehog and Beyond --plus multi-targeting cancer inhibitors

Site map of HSP90 Debio-0932 (CUDC-305)

News of HSP90 Debio-0932 (CUDC-305) » Forum : HSP90 Debio-0932 (CUDC-305)

Last 15 active topics

Login • Register

Statistics